Identification

Name
Chlorphenamine
Accession Number
DB01114  (APRD00001, DB09440)
Type
Small Molecule
Groups
Approved
Description

A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. [PubChem]

Structure
Thumb
Synonyms
  • 1-(p-chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
  • 1-(p-chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine
  • 2-[p-chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine
  • 3-(p-chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
  • Chlorophenylpyridamine
  • Chlorphenamin
  • Chlorphenaminum
  • Chlorpheniramine
  • Chlorpheniramine polistirex
  • Chlorpheniraminum
  • Clorfenamina
  • Clorfeniramina
  • γ-(4-chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine
  • γ-(4-chlorophenyl)-γ-(2-pyridyl)propyldimethylamine
Product Ingredients
IngredientUNIICASInChI Key
Chlorpheniramine gluconate79YPK3BAIT25387-68-2OCMSTKFGYJZBIY-IFWQJVLJSA-N
Chlorpheniramine hydrochloride5S6VUP419V56343-98-7NOXNCSQBTYNMHD-UHFFFAOYSA-N
Chlorpheniramine maleateV1Q0O9OJ9Z113-92-8DBAKFASWICGISY-BTJKTKAUSA-N
Chlorpheniramine tannate72JT935YTT1405-56-7KOOFUFFGNZKXFG-HBNMXAOGSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorpheniramine Maleate Injection USPLiquid10 mgIntramuscular; Intravenous; SubcutaneousOmega Laboratories LtdNot applicableNot applicableCanada
Chlortripolon Inj 10mg/mlLiquid10 mgIntramuscular; Intravenous; SubcutaneousSchering Plough1953-12-311999-08-04Canada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
4 Hour Allergy ReliefTablet4 mg/1OralBetter Living Brands1992-12-19Not applicableUs
Aller-chlorTablet4 mg/1OralRugby1992-12-19Not applicableUs
Aller-ChlorSyrup2 mg/5mLOralRugby2003-01-17Not applicableUs
Aller-chlorTablet4 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1992-12-19Not applicableUs
Aller-chlorSyrup2 mg/5mLOralRugby2014-03-20Not applicableUs
Aller-chlorTablet4 mg/1OralA-S Medication Solutions1992-12-19Not applicableUs
AllergyTablet4 mg/1OralRemedy Repack2017-07-07Not applicableUs
AllergyTablet4 mg/1OralHyvee1991-07-302018-03-01Us
AllergyTablet4 mg/1OralSUPERVALU INC.1992-12-19Not applicableUs
AllergyTablet4 mg/1OralAllegiant Health2014-12-15Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
999 Cold RemedyChlorpheniramine maleate (2 mg/6000mg) + Acetaminophen (100 mg/6000mg)CapsuleOralChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd.2003-07-03Not applicableUs
999 Cold Remedy GranularChlorpheniramine maleate (4 mg/90g) + Acetaminophen (200 mg/90g)GranuleOralChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd.2003-07-03Not applicableUs
999 Cold Remedy GranularChlorpheniramine maleate (4 mg/90g) + Acetaminophen (200 mg/90g)CapsuleOralChina Resources Sanjiu Medical & Pharmaceutical Co Ltd2003-07-032013-09-21Us
999 GANMAOLING ColdChlorpheniramine maleate (2 mg/1) + Acetaminophen (100 mg/1) + Caffeine (2 mg/1)CapsuleOralKingsway2012-07-30Not applicableUs
AccuHistChlorpheniramine maleate (1 mg/1mL) + Phenylephrine hydrochloride (2.5 mg/1mL)SolutionOralTiber Laboratories, LLC2010-01-252013-04-30Us
AccuHist PDXChlorpheniramine maleate (1 mg/1mL) + Dextromethorphan hydrobromide monohydrate (2.5 mg/1mL) + Phenylephrine hydrochloride (2.5 mg/1mL)SolutionOralTiber Laboratories, LLC2010-01-252013-04-30Us
Acetaminophen, Chlorpheniramine Maleate, Dextromethorphan Hydrobromide, Phenylephrine HydrochlorideChlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Tablet, coatedOralAAA Pharmaceutical, Inc.2012-12-28Not applicableUs
Acetaminophen, Chlorpheniramine Maleate, Dextromethorphan Hydrobromide, Phenylephrine HydrochlorideChlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Tablet, coatedOralAAA Pharmaceutical, Inc.2012-12-28Not applicableUs
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine HydrochlorideChlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Phenylephrine hydrochloride (5 mg/1)Tablet, coatedOralAAA Pharmaceutical, Inc.2012-12-28Not applicableUs
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine HydrochlorideChlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Phenylephrine hydrochloride (5 mg/1)Tablet, coatedOralAAA Pharmaceutical, Inc.2012-12-28Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Allergy DN IIChlorpheniramine maleate (4 mg/1) + Chlorpheniramine maleate (8 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1)KitBreckenridge Pharmaceutical, Inc.2008-11-012010-03-31Us
Allergy DN IIChlorpheniramine maleate (4 mg/1) + Chlorpheniramine maleate (8 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1)KitBreckenridge Pharmaceutical, Inc.2008-11-012010-03-31Us
Allergy DN PEChlorpheniramine maleate (8 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Phenylephrine hydrochloride (40 mg/1) + Phenylephrine hydrochloride (10 mg/1)KitBreckenridge Pharmaceutical, Inc.2008-11-012010-03-31Us
AlleRx Dose PackChlorpheniramine maleate (8 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Phenylephrine hydrochloride (10 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)KitOralCornerstone Therapeutics Inc.2008-02-012012-10-31Us
AlleRx Dose Pack DFChlorpheniramine maleate (4 mg/1) + Chlorpheniramine maleate (8 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1)KitOralCornerstone Therapeutics Inc.2006-08-012012-10-31Us
AlleRx Dose Pack DFChlorpheniramine maleate (4 mg/1) + Chlorpheniramine maleate (8 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1)KitOralCornerstone Therapeutics Inc.2006-08-012012-10-31Us
AlleRx Dose Pack PEChlorpheniramine maleate (8 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Phenylephrine hydrochloride (40 mg/1) + Phenylephrine hydrochloride (10 mg/1)KitOralCornerstone Therapeutics Inc.2006-09-012012-10-31Us
Atrohist PediatricChlorpheniramine tannate (2 mg/5mL) + Mepyramine tannate (12.5 mg/5mL) + Phenylephrine tannate (5 mg/5mL)SuspensionOralPhysicians Total Care, Inc.1994-09-232008-12-05Us
Atuss DS Tannate SuspensionChlorpheniramine maleate (4 mg/5mL) + Dextromethorphan hydrobromide monohydrate (30 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)SuspensionOralAtley Pharmaceuticals2006-11-21Not applicableUs
Atuss HS TannateChlorpheniramine maleate (4 mg/5mL) + Hydrocodone bitartrate (5 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)SuspensionOralAtley Pharmaceuticals2006-11-212009-08-03Us
International/Other Brands
Chlo-Amine / Chlor-Trimeton (Schering-Plough) / Clofeniramina / Haynon / Piriton (GlaxoSmithKline)
Categories
UNII
3U6IO1965U
CAS number
132-22-9
Weight
Average: 274.788
Monoisotopic: 274.123676325
Chemical Formula
C16H19ClN2
InChI Key
SOYKEARSMXGVTM-UHFFFAOYSA-N
InChI
InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
IUPAC Name
[3-(4-chlorophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
SMILES
CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1

Pharmacology

Indication

For the treatment of rhinitis, urticaria, allergy, common cold, asthma and hay fever.

Associated Conditions
Pharmacodynamics

In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Chlorpheniramine, is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

Mechanism of action

Chlorpheniramine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
USodium-dependent serotonin transporter
inhibitor
Human
USodium-dependent noradrenaline transporter
inhibitor
Human
USodium-dependent dopamine transporter
inhibitor
Human
Absorption

Well absorbed in the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding

72%

Metabolism

Primarily hepatic via Cytochrome P450 (CYP450) enzymes.

Route of elimination
Not Available
Half life

21-27 hours

Clearance
Not Available
Toxicity

Oral LD50 (rat): 306 mg/kg; Oral LD50 (mice): 130 mg/kg; Oral LD50 (guinea pig): 198 mg/kg [Registry of Toxic Effects of Chemical Substances. Ed. D. Sweet, US Dept. of Health & Human Services: Cincinatti, 2010.] Also a mild reproductive toxin to women of childbearing age.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Chlorphenamine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbexinostatThe risk or severity of QTc prolongation can be increased when Abexinostat is combined with Chlorphenamine.Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Chlorphenamine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Acetylglycinamide chloral hydrate.Experimental
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Chlorphenamine.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Adipiplon.Investigational
AgmatineThe serum concentration of Agmatine can be increased when it is combined with Chlorphenamine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alaproclate.Experimental
AlcaftadineThe risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Chlorphenamine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorphenamine.Approved, Illicit
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Chlorphenamine.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorphenamine.Approved, Illicit, Investigational
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Chlorphenamine.Approved
AmifampridineThe risk or severity of QTc prolongation can be increased when Amifampridine is combined with Chlorphenamine.Approved
AmikacinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Chlorphenamine.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amitriptylinoxide.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Chlorphenamine.Approved, Illicit
AmodiaquineThe risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Chlorphenamine.Approved, Investigational
AmoxapineThe risk or severity of QTc prolongation can be increased when Amoxapine is combined with Chlorphenamine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amperozide.Experimental
AmphetamineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Amphetamine.Approved, Illicit, Investigational
AmprenavirThe metabolism of Chlorphenamine can be decreased when combined with Amprenavir.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Anagrelide.Approved
AniracetamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Aniracetam.Experimental
AntazolineThe risk or severity of QTc prolongation can be increased when Antazoline is combined with Chlorphenamine.Approved
ApalutamideThe serum concentration of Chlorphenamine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Chlorphenamine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Chlorphenamine can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Arbekacin.Approved, Investigational
ArformoterolThe risk or severity of QTc prolongation can be increased when Arformoterol is combined with Chlorphenamine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Chlorphenamine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Chlorphenamine.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Atazanavir is combined with Chlorphenamine.Approved, Investigational
AtomoxetineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Chlorphenamine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Azaperone.Investigational, Vet Approved
AzatadineThe risk or severity of QTc prolongation can be increased when Azatadine is combined with Chlorphenamine.Approved
AZD-3043The risk or severity of adverse effects can be increased when Chlorphenamine is combined with AZD-3043.Investigational
AzelastineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Azithromycin is combined with Chlorphenamine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Chlorphenamine.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Barbital.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Beclamide.Experimental
BedaquilineThe risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Chlorphenamine.Approved
BekanamycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benactyzine.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Chlorphenamine.Approved
BenzoctamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benzoctamine.Approved
BenzphetamineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineChlorphenamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Chlorphenamine.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Chlorphenamine.Approved, Investigational
BetaxololThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Betaxolol.Approved, Investigational
BicalutamideThe metabolism of Chlorphenamine can be decreased when combined with Bicalutamide.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bifeprunox.Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Bilastine is combined with Chlorphenamine.Approved, Investigational
BL-1020The risk or severity of adverse effects can be increased when Chlorphenamine is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Blonanserin.Approved, Investigational
BoceprevirThe metabolism of Chlorphenamine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Chlorphenamine.Approved, Investigational
BosentanThe serum concentration of Chlorphenamine can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorphenamine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorphenamine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Chlorphenamine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brotizolam.Approved, Investigational, Withdrawn
BuclizineThe risk or severity of QTc prolongation can be increased when Buclizine is combined with Chlorphenamine.Approved
BufotenineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bufotenine.Experimental, Illicit
BuprenorphineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Chlorphenamine.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Buserelin is combined with Chlorphenamine.Approved, Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorphenamine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorphenamine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Chlorphenamine.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorphenamine.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Butriptyline.Approved
CalcitriolThe metabolism of Chlorphenamine can be increased when combined with Calcitriol.Approved, Nutraceutical
CamazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Camazepam.Approved, Illicit
CannabidivarinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Captodiame.Approved, Investigational
CarbamazepineThe metabolism of Chlorphenamine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Carbinoxamine.Approved
CarbromalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Chlorphenamine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Caroxazone.Withdrawn
CathinoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cathinone.Illicit
CeritinibThe serum concentration of Chlorphenamine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Chlorphenamine.Approved
CevimelineThe metabolism of Chlorphenamine can be decreased when combined with Cevimeline.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Chlorphenamine.Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorphenamine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of QTc prolongation can be increased when Chloroquine is combined with Chlorphenamine.Approved, Investigational, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chlorphenesin.Approved, Experimental
ChlorphentermineChlorphentermine may decrease the sedative and stimulatory activities of Chlorphenamine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Chlorphenamine.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Chlorphenamine.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Chlorphenamine.Approved, Nutraceutical
CholineThe serum concentration of Choline can be increased when it is combined with Chlorphenamine.Approved, Nutraceutical
Choline salicylateThe serum concentration of Choline salicylate can be increased when it is combined with Chlorphenamine.Approved, Nutraceutical
CilostazolThe risk or severity of QTc prolongation can be increased when Cilostazol is combined with Chlorphenamine.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Chlorphenamine.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Cinnarizine.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cinolazepam.Approved
CinoxacinThe risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Chlorphenamine.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Chlorphenamine.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cisatracurium.Approved
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Chlorphenamine.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Chlorphenamine.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Chlorphenamine.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Chlorphenamine.Approved, Illicit
Clobetasol propionateThe metabolism of Chlorphenamine can be increased when combined with Clobetasol propionate.Approved
clomethiazoleThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of QTc prolongation can be increased when Clomipramine is combined with Chlorphenamine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Chlorphenamine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorphenamine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorphenamine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Chlorphenamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of QTc prolongation can be increased when Clozapine is combined with Chlorphenamine.Approved
CobicistatThe metabolism of Chlorphenamine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Codeine.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Colistin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Chlorphenamine.Approved, Investigational
CrizotinibThe risk or severity of QTc prolongation can be increased when Crizotinib is combined with Chlorphenamine.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Chlorphenamine.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Chlorphenamine.Investigational
CurcuminThe metabolism of Chlorphenamine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of QTc prolongation can be increased when Cyclizine is combined with Chlorphenamine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclobenzaprine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Chlorphenamine.Approved
DabrafenibThe serum concentration of Chlorphenamine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Chlorphenamine can be decreased when combined with Danazol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Chlorphenamine.Investigational
DarunavirThe metabolism of Chlorphenamine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Chlorphenamine can be increased when it is combined with Dasatinib.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Chlorphenamine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Degarelix is combined with Chlorphenamine.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Delamanid is combined with Chlorphenamine.Approved, Investigational
DelavirdineThe metabolism of Chlorphenamine can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of QTc prolongation can be increased when Desflurane is combined with Chlorphenamine.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Desipramine is combined with Chlorphenamine.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe serum concentration of Chlorphenamine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Chlorphenamine.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Dexchlorpheniramine maleate.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dexmedetomidine.Approved, Vet Approved
DextofisopamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dextofisopam.Investigational
DextroamphetamineDextroamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.Approved, Illicit
DextromethorphanThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Chlorphenamine.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dichloralphenazone.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Chlorphenamine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Difenoxin.Approved, Illicit
DifloxacinThe risk or severity of QTc prolongation can be increased when Difloxacin is combined with Chlorphenamine.Vet Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorphenamine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Chlorphenamine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dimethyltryptamine.Experimental, Illicit
DiphenhydramineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorphenamine.Approved, Illicit
DisopyramideThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dixyrazine.Experimental
DofetilideThe metabolism of Dofetilide can be decreased when combined with Chlorphenamine.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Dolasetron is combined with Chlorphenamine.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Domoic Acid.Experimental
DomperidoneThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Donepezil is combined with Chlorphenamine.Approved
DopamineThe serum concentration of Dopamine can be increased when it is combined with Chlorphenamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of QTc prolongation can be increased when Dosulepin is combined with Chlorphenamine.Approved
DotarizineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doxacurium.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Doxepin.Approved, Investigational
DoxycyclineThe metabolism of Chlorphenamine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dyclonine.Approved
EbastineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Chlorphenamine.Approved, Investigational
EcopipamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Edivoxetine.Investigational
EfavirenzThe metabolism of Chlorphenamine can be decreased when combined with Efavirenz.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Eltanolone.Investigational
EmedastineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Emedastine.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Enflurane.Approved, Investigational, Vet Approved
EnoxacinThe risk or severity of QTc prolongation can be increased when Enoxacin is combined with Chlorphenamine.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Chlorphenamine.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Entinostat is combined with Chlorphenamine.Investigational
EnzalutamideThe serum concentration of Chlorphenamine can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of QTc prolongation can be increased when Epinastine is combined with Chlorphenamine.Approved, Investigational
EpinephrineThe serum concentration of Epinephrine can be increased when it is combined with Chlorphenamine.Approved, Vet Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Chlorphenamine.Approved, Nutraceutical
EribulinThe risk or severity of QTc prolongation can be increased when Eribulin is combined with Chlorphenamine.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Erlotinib.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Erythromycin is combined with Chlorphenamine.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Escitalopram.Approved, Investigational
EslicarbazepineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Eslicarbazepine.Approved
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Esmirtazapine.Investigational
EsmololThe risk or severity of QTc prolongation can be increased when Esmolol is combined with Chlorphenamine.Approved
EsreboxetineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Chlorphenamine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorphenamine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etacrynic acid.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethadione.Experimental
EthanolChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlorphenamine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Chlorphenamine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etoperidone.Withdrawn
EtoposideThe metabolism of Chlorphenamine can be increased when combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Chlorphenamine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of QTc prolongation can be increased when Ezogabine is combined with Chlorphenamine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fabomotizole.Experimental
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorphenamine.Approved
Fazadinium bromideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Febarbamate.Experimental
FelbamateThe risk or severity of QTc prolongation can be increased when Felbamate is combined with Chlorphenamine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fenyramidol.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorphenamine.Approved
FexofenadineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Fexofenadine.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Fingolimod is combined with Chlorphenamine.Approved, Investigational
FlecainideThe risk or severity of QTc prolongation can be increased when Flecainide is combined with Chlorphenamine.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Chlorphenamine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fluanisone.Experimental
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Chlorphenamine.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fludiazepam.Approved, Illicit
FlumequineThe risk or severity of QTc prolongation can be increased when Flumequine is combined with Chlorphenamine.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flunarizine.Approved
FlunisolideThe metabolism of Chlorphenamine can be increased when combined with Flunisolide.Approved, Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flunitrazepam.Approved, Illicit
Fluocinolone acetonideThe metabolism of Chlorphenamine can be increased when combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluorouracilThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Fluorouracil.Approved
FluoxetineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorphenamine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Chlorphenamine.Approved
FluvastatinThe metabolism of Chlorphenamine can be increased when combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of QTc prolongation can be increased when Formoterol is combined with Chlorphenamine.Approved, Investigational
FosamprenavirThe metabolism of Chlorphenamine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Chlorphenamine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Chlorphenamine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Chlorphenamine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Framycetin.Approved
FurazolidoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Furazolidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Chlorphenamine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of QTc prolongation can be increased when Gabapentin is combined with Chlorphenamine.Approved, Investigational
Gabapentin enacarbilThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gaboxadol.Investigational
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Chlorphenamine.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Chlorphenamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gallamine Triethiodide.Approved
Gamma hydroxybutyric acidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Chlorphenamine.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gantacurium Chloride.Investigational
GarenoxacinThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Chlorphenamine.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Chlorphenamine.Approved, Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gedocarnil.Experimental
GemifloxacinThe risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Chlorphenamine.Approved, Investigational
GeneticinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with GENTAMICIN C1A.Experimental
GepefrineGepefrine may decrease the sedative and stimulatory activities of Chlorphenamine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gepirone.Investigational
GivinostatThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Chlorphenamine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Glutethimide.Approved, Illicit
GoserelinThe risk or severity of QTc prolongation can be increased when Goserelin is combined with Chlorphenamine.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Granisetron is combined with Chlorphenamine.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Chlorphenamine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Halofantrine.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hexobarbital.Approved
HistamineThe serum concentration of Histamine can be increased when it is combined with Chlorphenamine.Approved, Investigational
HistrelinThe risk or severity of QTc prolongation can be increased when Histrelin is combined with Chlorphenamine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenamine.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hydracarbazine.Experimental
HydrocodoneChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
HydrocortisoneThe metabolism of Chlorphenamine can be increased when combined with Hydrocortisone.Approved, Vet Approved
HydromorphoneThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Chlorphenamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hypericin.Investigational
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorphenamine.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Ibutilide.Approved
IdelalisibThe metabolism of Chlorphenamine can be decreased when combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ifenprodil.Approved, Investigational, Withdrawn
IloperidoneThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Imagabalin.Investigational
ImatinibThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Imatinib.Approved
ImipramineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Imipramine.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Imipramine oxide.Experimental
IndacaterolThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Chlorphenamine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Chlorphenamine.Approved
IndinavirThe metabolism of Chlorphenamine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative and stimulatory activities of Chlorphenamine.Approved
IprindoleThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Iproniazid.Withdrawn
IsavuconazoleThe serum concentration of Chlorphenamine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Chlorphenamine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Chlorphenamine.Approved, Vet Approved
IsoniazidThe metabolism of Chlorphenamine can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Chlorphenamine.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Chlorphenamine.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Ivabradine.Approved
IvacaftorThe serum concentration of Chlorphenamine can be increased when it is combined with Ivacaftor.Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Chlorphenamine.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorphenamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Chlorphenamine.Approved, Investigational
KetotifenThe risk or severity of QTc prolongation can be increased when Ketotifen is combined with Chlorphenamine.Approved
L-TryptophanThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Chlorphenamine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorphenamine.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lanicemine.Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Lapatinib is combined with Chlorphenamine.Approved, Investigational
LenvatinibThe risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Chlorphenamine.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chlorphenamine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levetiracetam.Approved, Investigational
LevocabastineThe risk or severity of QTc prolongation can be increased when Levocabastine is combined with Chlorphenamine.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Chlorphenamine.Approved
LevodopaThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Levodopa.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Chlorphenamine.Approved, Investigational
Levomethadyl acetateThe risk or severity of QTc prolongation can be increased when Levomethadyl Acetate is combined with Chlorphenamine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorphenamine.Approved
LincomycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Linezolid.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the sedative and stimulatory activities of Chlorphenamine.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Lithium cation.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Chlorphenamine can be increased when used in combination with Lofexidine.Approved, Investigational
LomefloxacinThe risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Chlorphenamine.Approved, Investigational
LopinavirThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorphenamine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Chlorphenamine can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lortalamine.Experimental
LovastatinThe metabolism of Chlorphenamine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorphenamine.Approved
LuliconazoleThe serum concentration of Chlorphenamine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Chlorphenamine can be increased when combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lumateperone.Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorphenamine.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
MacimorelinThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Macimorelin.Approved, Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Chlorphenamine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of QTc prolongation can be increased when Maprotiline is combined with Chlorphenamine.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Chlorphenamine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Medifoxamine.Experimental
Medroxyprogesterone acetateThe metabolism of Chlorphenamine can be increased when combined with Medroxyprogesterone acetate.Approved, Investigational
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Chlorphenamine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Melperone.Approved, Investigational
MemantineThe serum concentration of Memantine can be increased when it is combined with Chlorphenamine.Approved, Investigational
MephedroneMephedrone may decrease the sedative and stimulatory activities of Chlorphenamine.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mephenoxalone.Experimental
MephentermineMephentermine may decrease the sedative and stimulatory activities of Chlorphenamine.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mephenytoin.Approved, Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorphenamine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Chlorphenamine.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Mequitazine is combined with Chlorphenamine.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Chlorphenamine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Chlorphenamine.Approved
MetforminThe serum concentration of Metformin can be increased when it is combined with Chlorphenamine.Approved
MethacyclineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of QTc prolongation can be increased when Methadone is combined with Chlorphenamine.Approved
Methadyl acetateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Chlorphenamine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorphenamine.Approved
MethotrimeprazineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative and stimulatory activities of Chlorphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methsuximide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methylphenobarbital.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methyprylon.Approved, Illicit, Withdrawn
MetoclopramideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Metoclopramide.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Metocurine Iodide.Approved, Withdrawn
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Chlorphenamine.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Chlorphenamine.Approved
MetyrosineChlorphenamine may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mianserin.Approved, Investigational
MibefradilThe metabolism of Chlorphenamine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Chlorphenamine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlorphenamine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative and stimulatory activities of Chlorphenamine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Chlorphenamine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved, Investigational
MirabegronThe risk or severity of QTc prolongation can be increased when Mirabegron is combined with Chlorphenamine.Approved
MirtazapineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Chlorphenamine can be decreased when it is combined with Mitotane.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mivacurium.Approved
MMDAMMDA may decrease the sedative and stimulatory activities of Chlorphenamine.Experimental, Illicit
MocetinostatThe risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Chlorphenamine.Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Chlorphenamine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Chlorphenamine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mosapramine.Experimental
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Chlorphenamine.Approved, Investigational
MRK-409The risk or severity of adverse effects can be increased when Chlorphenamine is combined with MRK-409.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved, Investigational
NafamostatThe serum concentration of Nafamostat can be increased when it is combined with Chlorphenamine.Approved, Investigational
NafcillinThe serum concentration of Chlorphenamine can be decreased when it is combined with Nafcillin.Approved, Investigational
NalbuphineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Nalbuphine.Approved
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Nalidixic Acid is combined with Chlorphenamine.Approved, Investigational
NaloxoneThe metabolism of Chlorphenamine can be decreased when combined with Naloxone.Approved, Vet Approved
NeamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nefiracetam.Investigational
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Chlorphenamine.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Chlorphenamine.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Chlorphenamine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Chlorphenamine can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Niaprazine.Experimental
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Chlorphenamine.Approved, Investigational
NilotinibThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Nilotinib.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlorphenamine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Chlorphenamine.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nordazepam.Approved
NorepinephrineThe serum concentration of Norepinephrine can be increased when it is combined with Chlorphenamine.Approved
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Chlorphenamine.Approved
NorgestimateThe metabolism of Chlorphenamine can be increased when combined with Norgestimate.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Octamoxin.Withdrawn
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorphenamine.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Chlorphenamine.Approved
OlanzapineThe risk or severity of QTc prolongation can be increased when Olanzapine is combined with Chlorphenamine.Approved, Investigational
OlaparibThe metabolism of Chlorphenamine can be decreased when combined with Olaparib.Approved
OlodaterolThe risk or severity of QTc prolongation can be increased when Olodaterol is combined with Chlorphenamine.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Chlorphenamine.Approved
OndansetronThe risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Chlorphenamine.Approved
OpipramolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Opium.Approved, Illicit
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Chlorphenamine.Vet Approved
OrphenadrineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Chlorphenamine can be increased when it is combined with Osimertinib.Approved
OxaflozaneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxaflozane.Experimental
OxaliplatinThe risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Chlorphenamine.Approved, Investigational
OxaprotilineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxaprotiline.Experimental
OxatomideThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Oxatomide.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorphenamine.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxitriptan.Approved, Investigational, Nutraceutical
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Chlorphenamine.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxprenolol.Approved
OxycodoneThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxypertine.Experimental
OxytetracyclineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxytetracycline.Approved, Investigational, Vet Approved
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorphenamine.Approved, Vet Approved
PalbociclibThe serum concentration of Chlorphenamine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pancuronium.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Panobinostat is combined with Chlorphenamine.Approved, Investigational
PapaverineThe risk or severity of QTc prolongation can be increased when Papaverine is combined with Chlorphenamine.Approved, Investigational
ParaldehydeChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Paroxetine.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Pasireotide is combined with Chlorphenamine.Approved
PazopanibThe risk or severity of QTc prolongation can be increased when Pazopanib is combined with Chlorphenamine.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Chlorphenamine.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Chlorphenamine.Approved
PegvisomantThe metabolism of Chlorphenamine can be increased when combined with Pegvisomant.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Penimepicycline.Experimental
PentamidineThe risk or severity of QTc prolongation can be increased when Pentamidine is combined with Chlorphenamine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorphenamine.Approved, Vet Approved
PentobarbitalThe metabolism of Chlorphenamine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
PerazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Perazine.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Perflutren is combined with Chlorphenamine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorphenamine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorphenamine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pheniprazine.Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Chlorphenamine.Approved
PhenobarbitalThe metabolism of Chlorphenamine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenoperidine.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phensuximide.Approved
PhentermineThe risk or severity of serotonin syndrome can be increased when Phentermine is combined with Chlorphenamine.Approved, Illicit
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Chlorphenamine.Approved, Vet Approved
PimavanserinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Pimozide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pinazepam.Experimental
PindololThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipecuronium.Approved
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Chlorphenamine.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pirlindole.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Chlorphenamine.Experimental
PitolisantThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Chlorphenamine.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pizotifen.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Plazomicin.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pomalidomide.Approved
PosaconazoleThe risk or severity of QTc prolongation can be increased when Posaconazole is combined with Chlorphenamine.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Pracinostat is combined with Chlorphenamine.Investigational
PramipexoleChlorphenamine may increase the sedative activities of Pramipexole.Approved, Investigational
PravastatinThe metabolism of Pravastatin can be decreased when combined with Chlorphenamine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Chlorphenamine.Approved
PregabalinThe therapeutic efficacy of Chlorphenamine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pridinol.Experimental
PrimaquineThe risk or severity of QTc prolongation can be increased when Primaquine is combined with Chlorphenamine.Approved
PrimidoneThe metabolism of Chlorphenamine can be increased when combined with Primidone.Approved, Vet Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Probucol is combined with Chlorphenamine.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Prochlorperazine.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Progabide.Approved, Investigational
PromazineThe risk or severity of QTc prolongation can be increased when Promazine is combined with Chlorphenamine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Promethazine.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Chlorphenamine.Approved
PropanididThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Propanidid.Experimental
PropericiazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Propericiazine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Propiopromazine.Vet Approved
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Chlorphenamine.Approved, Investigational, Vet Approved
PropranololThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of QTc prolongation can be increased when Protriptyline is combined with Chlorphenamine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Proxibarbal.Experimental
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Chlorphenamine.Investigational
PseudoephedrineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Pseudoephedrine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Chlorphenamine.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Quetiapine.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Chlorphenamine.Approved
RanolazineThe risk or severity of QTc prolongation can be increased when Ranolazine is combined with Chlorphenamine.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rapacuronium.Approved, Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rasagiline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorphenamine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Remoxipride.Approved, Withdrawn
ReposalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorphenamine.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Ribociclib.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ribostamycin.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Chlorphenamine.Investigational
RifampicinThe metabolism of Chlorphenamine can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Chlorphenamine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Chlorphenamine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Chlorphenamine can be increased when combined with Rifaximin.Approved, Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Chlorphenamine.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Riluzole.Approved, Investigational
RimexoloneThe metabolism of Chlorphenamine can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative and stimulatory activities of Chlorphenamine.Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Chlorphenamine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rizatriptan.Approved
RocuroniumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rolitetracycline.Approved
RomidepsinThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Romidepsin.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Romifidine.Vet Approved
RopiniroleChlorphenamine may increase the sedative activities of Ropinirole.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Chlorphenamine.Approved, Investigational
RotigotineChlorphenamine may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Chlorphenamine.Approved, Investigational, Withdrawn
RP-5063The risk or severity of adverse effects can be increased when Chlorphenamine is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorphenamine.Approved
RufloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Chlorphenamine.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Rupatadine is combined with Chlorphenamine.Approved
SafinamideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Safrazine.Withdrawn
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Chlorphenamine.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Chlorphenamine.Approved
SaquinavirThe risk or severity of QTc prolongation can be increased when Saquinavir is combined with Chlorphenamine.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Chlorphenamine.Vet Approved, Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Saredutant.Investigational
SarilumabThe therapeutic efficacy of Chlorphenamine can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorphenamine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Sertraline.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Chlorphenamine.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be decreased when combined with Chlorphenamine.Approved, Investigational
SiltuximabThe serum concentration of Chlorphenamine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Chlorphenamine can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sisomicin.Investigational
SitafloxacinThe risk or severity of QTc prolongation can be increased when Sitafloxacin is combined with Chlorphenamine.Experimental, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
SolifenacinThe risk or severity of QTc prolongation can be increased when Solifenacin is combined with Chlorphenamine.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Chlorphenamine.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Sparfloxacin.Approved, Investigational
St. John's WortThe serum concentration of Chlorphenamine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Chlorphenamine can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorphenamine.Approved, Investigational
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Chlorphenamine.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Chlorphenamine.Approved, Vet Approved
SulpirideThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Chlorphenamine.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sulthiame.Experimental
SultoprideThe risk or severity of QTc prolongation can be increased when Sultopride is combined with Chlorphenamine.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of QTc prolongation can be increased when Sunitinib is combined with Chlorphenamine.Approved, Investigational
SuvorexantChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Talopram.Experimental
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Chlorphenamine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tandospirone.Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Tandutinib is combined with Chlorphenamine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tasimelteon.Approved, Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Chlorphenamine.Investigational
TelaprevirThe metabolism of Chlorphenamine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinThe risk or severity of QTc prolongation can be increased when Telavancin is combined with Chlorphenamine.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Telithromycin is combined with Chlorphenamine.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Temafloxacin.Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorphenamine.Approved, Investigational
TerbinafineThe metabolism of Chlorphenamine can be increased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Chlorphenamine.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Terfenadine.Approved, Withdrawn
TerlipressinThe risk or severity of QTc prolongation can be increased when Terlipressin is combined with Chlorphenamine.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Terodiline.Experimental
TetrabenazineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Tetrabenazine.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetracycline.Approved, Vet Approved
TetraethylammoniumThe serum concentration of Tetraethylammonium can be increased when it is combined with Chlorphenamine.Experimental, Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrodotoxin.Investigational
ThalidomideChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thioproperazine.Approved
ThioridazineChlorphenamine may increase the arrhythmogenic activities of Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Thiothixene is combined with Chlorphenamine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Chlorphenamine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tiapride.Approved, Investigational
TigecyclineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tilidine.Experimental
TipranavirThe metabolism of Chlorphenamine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Chlorphenamine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Chlorphenamine can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tofisopam.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorphenamine.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tolperisone.Approved, Investigational
TolterodineThe risk or severity of QTc prolongation can be increased when Tolterodine is combined with Chlorphenamine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Chlorphenamine.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tramadol.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of serotonin syndrome can be increased when Trazodone is combined with Chlorphenamine.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Chlorphenamine.Approved, Investigational
TriamcinoloneThe metabolism of Chlorphenamine can be increased when combined with Triamcinolone.Approved, Vet Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorphenamine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Triclofos.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorphenamine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trimethadione.Approved
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Chlorphenamine.Approved, Vet Approved
TrimipramineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Triprolidine is combined with Chlorphenamine.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Triptorelin is combined with Chlorphenamine.Approved, Vet Approved
TroleandomycinThe metabolism of Chlorphenamine can be decreased when combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tubocurarine.Approved
TucidinostatThe risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Chlorphenamine.Investigational
ValerianThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Valerian.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Valnoctamide.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vancomycin.Approved
VandetanibThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Chlorphenamine.Approved
VareniclineChlorphenamine may decrease the excretion rate of Varenicline which could result in a higher serum level.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vecuronium.Approved
VemurafenibThe serum concentration of Chlorphenamine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Veralipride.Experimental
VerapamilThe metabolism of Chlorphenamine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Chlorphenamine.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Vilanterol is combined with Chlorphenamine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vinylbital.Experimental
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Chlorphenamine.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Vorinostat is combined with Chlorphenamine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vortioxetine.Approved, Investigational
XP19986The risk or severity of adverse effects can be increased when Chlorphenamine is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Xylazine.Vet Approved
YohimbineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorphenamine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zolmitriptan.Approved, Investigational
ZolpidemChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Chlorphenamine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Chlorphenamine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

Synthesis Reference

Anil M. Salpekar, John Johnson, "Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom." U.S. Patent US4631284, issued April, 1975.

US4631284
General References
  1. MSDS [Link]
External Links
Human Metabolome Database
HMDB0001944
KEGG Drug
D07398
KEGG Compound
C06905
PubChem Compound
2725
PubChem Substance
46508253
ChemSpider
2624
BindingDB
35938
ChEBI
52010
ChEMBL
CHEMBL505
Therapeutic Targets Database
DAP000336
PharmGKB
PA448960
IUPHAR
1213
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Chlorpheniramine
ATC Codes
R06AB54 — Chlorphenamine, combinationsR06AB04 — Chlorphenamine
AHFS Codes
  • 04:04.20 — Propylamine Derivatives
MSDS
Download (72.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers4
1Not Yet RecruitingTreatmentAdenocarcinoma Of Esophagus / Squamous Cell Carcinoma (SCC) / Tumors, Solid1
1Not Yet RecruitingTreatmentBladder Small Cell Neuroendocrine Carcinoma / Castration-Resistant Prostate Carcinoma / Metastatic Bladder Urothelial Carcinoma / Metastatic Urethral Urothelial Carcinoma / Prostate Carcinoma Metastatic in the Bone / Prostate Neuroendocrine Neoplasm / Prostate Small Cell Carcinoma / Stage III Bladder Cancer AJCC v8 / Stage III Prostate Cancer AJCC v8 / Stage III Urethral Cancer AJCC v8 / Stage IV Bladder Cancer AJCC v8 / Stage IV Prostate Cancer AJCC v8 / Stage IV Urethral Cancer AJCC v8 / Stage IVA Bladder Cancer AJCC v8 / Stage IVB Bladder Cancer AJCC v8 / Transitional Cell Carcinoma / Ureter Small Cell Carcinoma1
1, 2Not Yet RecruitingTreatmentCancer of the Ovary1
2CompletedTreatmentAllergic Reactions1
2Not Yet RecruitingTreatmentCancer, Breast / Estrogen Receptor Positive Tumor / Her2-Positive Breast Cancer1
2Not Yet RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Metastatic Breast Cancer (MBC) / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Triple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentNasal Cavity Adenocarcinoma / Nasal Cavity Tumor / Paranasal Sinus Cancer1
2RecruitingTreatmentSunburn1
2TerminatedTreatmentAllergic Rhinitis (AR)1
2Unknown StatusTreatmentRhinitis, Seasonal, Allergic1
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
3Not Yet RecruitingTreatmentCervical Cancers1
3Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cancer1
3Unknown StatusTreatmentAcute Rhinitis / Flu-like Syndromes1
3WithdrawnTreatmentAcute Rhinitis1
4CompletedPreventionAcellular Pertussis / Diphtheria / Healthy Volunteers / Tetanus1
4RecruitingPreventionProtamine Adverse Reaction1
4Unknown StatusTreatmentVitiligo1
Not AvailableCompletedBasic ScienceHypovolaemia / Temperature Change, Body1
Not AvailableCompletedTreatmentPeriodontitis1
Not AvailableUnknown StatusPreventionPoisoning1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Amend
  • Anip Acquisition Co.
  • A-S Medication Solutions LLC
  • Breckenridge Pharmaceuticals
  • C.O. Truxton Inc.
  • Cardinal Health
  • Consolidated Midland Corp.
  • Contract Pharm
  • Cypress Pharmaceutical Inc.
  • Deltex Pharmaceuticals Inc.
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Edwards Pharmaceuticals
  • Hi Tech Pharmacal Co. Inc.
  • Iopharm Laboratories Inc.
  • Ivax Pharmaceuticals
  • Kowa Pharmaceuticals America Inc.
  • Kraft Pharmaceutical Co. Inc.
  • Larken Laboratories Inc.
  • Liberty Pharmaceuticals
  • Magna Pharmaceuticals
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • McNeil Laboratories
  • Meda AB
  • Misemer Pharmaceuticals Inc.
  • Mismer Pharmace
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pecos Pharmaceutical Inc.
  • Perrigo Co.
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Provident Pharmaceuticals LLC
  • Qualitest
  • Rico Pharmacal
  • River's Edge Pharmaceuticals
  • Rugby Laboratories
  • S&P Healthcare
  • Schering-Plough Inc.
  • Time-Cap Labs
  • Tya Pharmaceuticals
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
SolutionOral
Granule, effervescentOral
SyrupOral2 mg/5mL
Capsule, gelatin coatedOral
Tablet, coatedOral4 mg/1
Tablet, coatedOral
KitOral
Liquid; tabletIntramuscular; Oral; Subcutaneous
Liquid; tabletOral; Parenteral
SyrupOral
Granule, for solutionOral
LiquidTopical
SuspensionOral
Tablet, extended releaseOral12 mg/1
Tablet, extended releaseOral12 mg
Kit; tablet; tablet, extended releaseOral
TabletOral12 mg
Solution / dropsOral
TabletOral4 mg/1
Tablet, film coated, extended releaseOral12 mg/1
LiquidIntramuscular; Intravenous; Subcutaneous10 mg
SyrupOral2.5 mg
Kit; tabletOral
Tablet, extended releaseOral
Tablet, sugar coatedOral
Capsule, liquid filledOral
Solution / dropsNasal
LozengeOral2 mg/1
Kit; powder, for solutionOral
Tablet, film coatedOral
CapsuleOral
LiquidOral2 mL/1mL
LiquidOral2 mg/5mL
Tablet, effervescentOral
Kit; powderOral
Powder, for solutionOral
GranuleOral
CapsuleOral1.25 mg/1
PowderOral
Tablet, chewableOral
Capsule, delayed release pelletsOral
Tablet, film coatedOral4 mg/1
Tablet, multilayerOral
TabletOral4 mg
Capsule, extended releaseOral
Tablet, multilayer, extended releaseOral
TabletOral
Suspension, extended releaseOral
SuspensionOral1000 mg/1
Kit
LiquidOral
Prices
Unit descriptionCostUnit
Ahist 12 mg tablet1.1USD tablet
Myci chlor-tan 8 mg caplet0.75USD caplet
Chlorpheniramine powder0.67USD g
Chlor-trimeton allergy0.31USD each
Chlor-trimeton 8 mg repetab0.24USD tablet
Aller-chlor 4 mg tablet0.06USD tablet
Pediacare allergy solution0.05USD ml
Allergy 4 mg tablet0.04USD tablet
Chlorpheniramine 4 mg tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7863287No2007-02-282027-02-28Us
US8062667No2009-03-292029-03-29Us
US8790700No2007-03-152027-03-15Us
US9066942No2012-01-032032-01-03Us
US6383471No1999-04-062019-04-06Us
US6248363No1999-11-232019-11-23Us
US9107921No2012-01-032032-01-03Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
boiling point (°C)142 °CNot Available
water solubility5500 mg/L (at 37 °C)BEILSTEIN
logP3.38HANSCH,C ET AL. (1995)
pKa9.13 (at 25 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility0.0519 mg/mLALOGPS
logP3.74ALOGPS
logP3.58ChemAxon
logS-3.7ALOGPS
pKa (Strongest Basic)9.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity80.85 m3·mol-1ChemAxon
Polarizability30.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9754
Blood Brain Barrier+0.962
Caco-2 permeable+0.8749
P-glycoprotein substrateSubstrate0.6136
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.9376
Renal organic cation transporterInhibitor0.7916
CYP450 2C9 substrateNon-substrate0.8026
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6472
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9096
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9023
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7501
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9183
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.3361 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8702
hERG inhibition (predictor II)Inhibitor0.7145
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0zfr-6290000000-2ca3230cde716588805e
Mass Spectrum (Electron Ionization)MSsplash10-0zfr-6490000000-8e58cd1c686f23a7dac6
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-01b9-3900000000-ea4ccfd2afe05f49fc7a
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-004i-0090000000-9e46eb080de95d4f8f8e
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-014i-1920000000-d2d2acf559d9070a1d47
MS/MS Spectrum - EI-B (Unknown) , PositiveLC-MS/MSsplash10-0zfr-6190000000-2ca3230cde716588805e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0290000000-03651b7b90a1745fdf23
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0uy0-0960000000-1f750af75fe542c6c06f
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pheniramines
Direct Parent
Pheniramines
Alternative Parents
Chlorobenzenes / Aralkylamines / Aryl chlorides / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Pheniramine / Chlorobenzene / Halobenzene / Aralkylamine / Aryl chloride / Benzenoid / Monocyclic benzene moiety / Aryl halide / Heteroaromatic compound / Tertiary aliphatic amine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
tertiary amino compound, pyridines, monochlorobenzenes (CHEBI:52010)

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y, Arai H, Iwata R, Fujii T, Komemushi S, Ido T, Itoh M, Sasaki H, Watanabe T, Yanai K: Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. Br J Clin Pharmacol. 2001 Nov;52(5):501-9. [PubMed:11736858]
  3. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF 3rd, Guinosso PJ Jr, Lynch JJ Jr: Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 1995 Jan;76(1):110-9. [PubMed:8001268]
  4. Hasenohrl RU, Kuhlen A, Frisch C, Galosi R, Brandao ML, Huston JP: Comparison of intra-accumbens injection of histamine with histamine H1-receptor antagonist chlorpheniramine in effects on reinforcement and memory parameters. Behav Brain Res. 2001 Oct 15;124(2):203-11. [PubMed:11640974]
  5. Yasuda SU, Wellstein A, Likhari P, Barbey JT, Woosley RL: Chlorpheniramine plasma concentration and histamine H1-receptor occupancy. Clin Pharmacol Ther. 1995 Aug;58(2):210-20. [PubMed:7648771]
  6. Nicholson AN, Pascoe PA, Turner C, Ganellin CR, Greengrass PM, Casy AF, Mercer AD: Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol. 1991 Sep;104(1):270-6. [PubMed:1686208]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J: In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos. 1998 Jun;26(6):536-9. [PubMed:9616188]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]

Drug created on June 13, 2005 07:24 / Updated on September 17, 2018 20:51